Related Experiment Video

Updated: May 6, 2026

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

10.0K

Increased autophagy accelerates colchicine-induced muscle toxicity

James K Ching, Jeong Sun Ju, Sara K Pittman

    Autophagy
    |November 5, 2013
    PubMed

    Insights

    Colchicine can cause muscle damage by disrupting autophagy. Combining colchicine with drugs like rapamycin or statins worsens this effect, leading to muscle necrosis due to impaired autophagosome clearance.

    Area of Science:

    • Cell Biology
    • Toxicology
    • Muscle Physiology

    Background:

    • Colchicine treatment is linked to autophagic vacuolar myopathy in humans.
    • This myopathy is thought to result from microtubule destabilization, impairing autophagosome-lysosome fusion and causing autophagic vacuoles to accumulate.
    • Statins are frequently used alongside colchicine in patients with myopathy.

    Purpose of the Study:

    • To investigate the mechanism of colchicine-induced myotoxicity.
    • To explore the role of autophagy modulation in colchicine myopathy.
    • To determine if statins exacerbate colchicine-induced muscle damage.

    Main Methods:

    • Utilized the mTOR inhibitor rapamycin to augment colchicine's myotoxic effect in vitro.
    • Examined autophagic substrate accumulation (LC3-II, SQSTM1) and autophagosome-lysosome fusion (LAMP2 colocalization) in myofibers.
    • Administered colchicine and simvastatin to mice to assess myotoxicity and autophagy markers.
    • Investigated the effect of four different statins on skeletal muscle autophagic flux in vivo.

    Main Results:

    • Rapamycin enhanced colchicine's myotoxic effect, causing acute myopathy and muscle necrosis with autophagic substrate accumulation.
    • Myonecrosis induced by rapamycin and colchicine showed central LC3 accumulation and failed colocalization with LAMP2, mirroring human colchicine myopathy.
    • Simvastatin and other statins induced muscle necrosis and LC3 accumulation in mice, indicating they activate autophagy.
    • Statin treatment enhanced skeletal muscle autophagic flux in vivo.

    Conclusions:

    • Simultaneous activation of autophagy and inhibition of autophagosome degradation by drug combinations can lead to myotoxicity.
    • Polypharmacy involving colchicine and autophagy-modulating drugs (like statins) presents a risk for toxic myopathies.
    • Understanding these drug interactions is crucial for preventing medication-induced muscle damage.

    More Related Videos

    Activating Autophagy by Aerobic Exercise in Mice08:44

    Activating Autophagy by Aerobic Exercise in Mice

    Published on: February 3, 2017

    12.1K
    Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

    Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

    Published on: June 30, 2023

    1.5K

    Related Concept Videos

    Drugs that Destabilize Microtubules01:10

    Drugs that Destabilize Microtubules

    Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
    3.2K
    Autophagic Cell Death01:18

    Autophagic Cell Death

    Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
    Autophagy and Apoptosis
    Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
    3.3K
    Autophagy01:27

    Autophagy

    Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
    An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
    5.1K
    Cellular Injury V: Apoptosis and Autophagy01:22

    Cellular Injury V: Apoptosis and Autophagy

    Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
    121
    Drug Toxicity: Dose-Dependent Reactions01:24

    Drug Toxicity: Dose-Dependent Reactions

    Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
    245
    Anticholinesterase Agents: Poisoning and Treatment01:26

    Anticholinesterase Agents: Poisoning and Treatment

    Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
    Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
    2.0K